FCGR2B and diabetes mellitus: Collectively, these results establish that FCGR2B knockdown rectifies diabetes-induced hippocampal excitatory dysfunction by modulating the expression balance between excitatory and inhibitory neuronal markers, thereby identifying FCGR2B as a novel therapeutic target for diabetes-associated cognitive impairment.